# Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

> **NCT04542213** · PHASE3 · COMPLETED · sponsor: **Hospital Regional de Alta Especialidad del Bajio** · enrollment: 70 (actual)

## Conditions studied

- Hyperglycemia
- Covid19

## Interventions

- **DRUG:** Linagliptin tablet
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT04542213
- **Lead sponsor:** Hospital Regional de Alta Especialidad del Bajio
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542213, "Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04542213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*